{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:31:01Z","timestamp":1791873061908,"version":"4.3.4"},"reference-count":33,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T00:00:00Z","timestamp":1580774400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>To compare the benefits and harms of naltrexone\u2013bupropion using evidence from clinical study reports.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We searched Food and Drug Administration and European Medicines Agency websites, PubMed, and Clinicaltrials.gov (May 2016) to identify pivotal trials; we then sent a freedom of information request to the European Medicines Agency (July 2016). We included pivotal, phase III placebo\u2010controlled trials. We assessed the risks of bias using the Cochrane criteria, and the quality of the evidence using GRADE. We used a random\u2010effects model for meta\u2010analyses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Over a 27\u2010month period (July 2016 to August 2018), we received 31 batches of clinical study report documents containing over 65 000 pages of data from 4 pivotal trials (<jats:italic>n<\/jats:italic> = 4536). Significantly more participants who took naltrexone\u2013bupropion achieved \u22655% reduction in body weight: risk ratio (RR) = 2.1 (95% confidence interval 1.35\u20133.28), <jats:italic>P =<\/jats:italic> .001, GRADE = low, number needed to treat (NNT) to benefit = 5 (3\u201317); this represents a 2.53 kg (1.85\u20133.21) reduction in baseline body weight compared with placebo. Naltrexone\u2013bupropion had significantly beneficial effects on other cardiovascular risk factors; however, the true effect sizes for these are uncertain because of incomplete outcome data. Naltrexone\u2013bupropion significantly increased the risk of adverse events: RR = 1.11 (1.05\u20131.18, <jats:italic>P =<\/jats:italic> .0004, GRADE = low, NNT to harm = 12 7\u201327); serious adverse events: RR = 1.70 (1.38\u20132.1, <jats:italic>P &lt;<\/jats:italic> .00001, GRADE = moderate, NNT to harm = 21 13\u201338); and discontinuation because of adverse events: RR = 1.92 (1.65\u20132.24, <jats:italic>P &lt;<\/jats:italic> .00001, GRADE = moderate, NNT to discontinue treatment = 9 8\u201313).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Naltrexone\u2013bupropion significantly reduces body weight by a small amount but significantly increases the risk of adverse events. A rigorous process of postmarketing surveillance is required.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.14210","type":"journal-article","created":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T22:29:27Z","timestamp":1578608967000},"page":"646-667","source":"Crossref","is-referenced-by-count":68,"title":["Naltrexone\u2013bupropion (Mysimba) in management of obesity: A systematic review and meta\u2010analysis of unpublished clinical study reports"],"prefix":"10.1111","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2420-0811","authenticated-orcid":false,"given":"Igho J.","family":"Onakpoya","sequence":"first","affiliation":[{"name":"Centre for Evidence\u2010Based Medicine, Nuffield Department of Primary Care Health Sciences, Radcliffe Observatory Quarter University of Oxford  Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Lee","sequence":"additional","affiliation":[{"name":"Centre for Evidence\u2010Based Medicine, Nuffield Department of Primary Care Health Sciences, Radcliffe Observatory Quarter University of Oxford  Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal R.","family":"Mahtani","sequence":"additional","affiliation":[{"name":"Centre for Evidence\u2010Based Medicine, Nuffield Department of Primary Care Health Sciences, Radcliffe Observatory Quarter University of Oxford  Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1139-655X","authenticated-orcid":false,"given":"Jeffrey K.","family":"Aronson","sequence":"additional","affiliation":[{"name":"Centre for Evidence\u2010Based Medicine, Nuffield Department of Primary Care Health Sciences, Radcliffe Observatory Quarter University of Oxford  Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl J.","family":"Heneghan","sequence":"additional","affiliation":[{"name":"Centre for Evidence\u2010Based Medicine, Nuffield Department of Primary Care Health Sciences, Radcliffe Observatory Quarter University of Oxford  Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,2,4]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60460-8"},{"key":"e_1_2_9_3_1","unstructured":"World Health Organization.Obesity and overweight. Key facts.16 February 2018.https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/obesity-and-overweight[Accessed 12 February 2019]"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13679-013-0062-y"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-016-0735-y"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2013.145"},{"key":"e_1_2_9_7_1","unstructured":"National Institute for Health and Care Excellence.Final appraisal determination. Naltrexone\u2013bupropion for managing overweight and obesity. Available at:https:\/\/www.nice.org.uk\/guidance\/gid-tag486\/documents\/final-appraisal-determination-document[Accessed 3 October 2017]"},{"key":"e_1_2_9_8_1","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human use.ICH Harmonised Tripartite Guideline. Structure and Content of Clinical Study Reports E3. Current Step 4 version.30 November 1995. Available at:http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E3\/E3_Guideline.pdf[Accessed 3 October 2017]"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002127"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-016-1327-z"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"e_1_2_9_12_1","unstructured":"Cochrane Handbook of Systematic Reviews.How to include multiple groups from one study. Chapter 16 (Section 5.4).http:\/\/handbook.cochrane.org\/chapter_16\/16_5_4_how_to_include_multiple_groups_from_one_study.htm[Accessed 20 June 2017]"},{"key":"e_1_2_9_13_1","unstructured":"Review Manager (RevMan) [Computer program].Version 5.3. Copenhagen: The Nordic Cochrane Centre The Cochrane Collaboration 2014."},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.328.7454.1490"},{"key":"e_1_2_9_15_1","unstructured":"GRADEpro.Computer programonwww.gradepro.org.Version 3.6. McMaster University 2014."},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60888-4"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2010.147"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.20309"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-0234"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-12-9"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-017-0442-1"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/1740774512450098"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.7602"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22118"},{"key":"e_1_2_9_25_1","unstructured":"LeBlancEL PatnodeCD WebberEM RedmondN RushkinM O'ConnorEA.Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 Sep. Report No.: 18\u201005239\u2010EF\u20101. Behavioral and Pharmacotherapy Weight Loss Interventions to Prevent Obesity\u2010Related Morbidity and Mortality in Adults: An Updated Systematic Review for the U.S. Preventive Services Task Force Available at:https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK532379\/[Accessed 29 November 2019]"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-8-16"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13142-015-0353-9"},{"key":"e_1_2_9_28_1","unstructured":"Contrave\u00ae.Full Prescribing Information. Available at:https:\/\/contravehcp.com\/wp-content\/uploads\/member-content\/Contrave_PI_MedGuide.pdf[Accessed 8 September 2019]"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.1558"},{"key":"e_1_2_9_30_1","unstructured":"Naltrexone\/Bupropion Cardiovascular Outcomes Study.ClinicalTrials.govwebsite.https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02638129?term=NCT02638129&rank=1. Updated 27 February 2017. 20 November 2018."},{"issue":"3","key":"e_1_2_9_31_1","first-page":"164","article-title":"Naltrexone\/bupropion ER (Contrave): newly approved treatment option for chronic weight management in obese adults","volume":"41","author":"Sherman MM","year":"2016","journal-title":"P t"},{"key":"e_1_2_9_32_1","unstructured":"US Securities and Exchange Commission.Form 8K [filed by Orexigen Therapeutics Inc]. March 3 2015.https:\/\/www.sec.gov\/Archives\/edgar\/data\/1382911\/000119312515074251\/d882841d8k.htm. [Accessed 20 November 2018]"},{"key":"e_1_2_9_33_1","unstructured":"Orexigen.Press Release. Orexigen Therapeutics Inc. Enters Agreement for Sale of Company.http:\/\/ir.orexigen.com\/phoenix.zhtml?c=207034&p=irol-newsArticle[Accessed 23 November 2018]"},{"key":"e_1_2_9_34_1","unstructured":"National Centre for Pharmacoeconomics NCPE Ireland.Naltrexone\/bupropion (Mysimba\u00ae).www.ncpe.ie\/drugs\/naltrexone-bupropion-mysimba\/[Accessed 20 November 2019]"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14210","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.14210","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14210","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T13:55:46Z","timestamp":1693922146000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.14210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,4]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.1111\/bcp.14210"],"URL":"https:\/\/doi.org\/10.1111\/bcp.14210","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,4]]}}}